Bone Marrow Transplant. 1990 Apr;5(4):265-8.

High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.

Ventura GJ, Barlogie B, Hester JP, Yau JC, LeMaistre CF, Wallerstein RO, Spinolo JA, Dicke KA, Horwitz LH, Alexanian R.

Source

Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston.

Abstract

Eleven patients with advanced multiple myeloma refractory to standard doses of alkylating agents and salvage therapy with vincristine, adriamycin and dexamethasone (VAD) were treated with high dose cyclophosphamide, BCNU and VP-16 (CBV) with autologous blood stem cell support. Seven patients had marked marrow plasmacytosis (greater than 30%) and four had extensive pelvic bone disease precluding autologous marrow harvest. Four patients responded with a median remission duration of 7 months. Recovery of granulocytes and platelets occurred promptly in 10 evaluable patients with complete hematologic recovery. Autologous blood stem cells can provide safe and effective support for high dose CBV treatment of myeloma patients with extensive marrow plasmacytosis. The short remissions call for better cytoreductive regimens with consideration for earlier use when the myeloma may be more responsive to therapy.

PMID:: 1970939; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Other Literature Sources

COS Scholar Universe

Medical

Multiple Myeloma - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma. [Cancer. 1996]
High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma.
Long GD, Chao NJ, Hu WW, Negrin RS, Wong RM, Blume KG. Cancer. 1996 Dec 15; 78(12):2502-9.
Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. [Leuk Lymphoma. 2005]
Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma.
Robertson MJ, Abonour R, Hromas R, Nelson RP, Fineberg NS, Cornetta K. Leuk Lymphoma. 2005 Oct; 46(10):1477-87.
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma. [J Clin Oncol. 1994]
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Adkins DR, Salzman D, Boldt D, Kuhn J, Irvin R, Roodman GD, Lyons R, Smith L, Freytes CO, LeMaistre CF. J Clin Oncol. 1994 Sep; 12(9):1890-901.
Review High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma. [Ann Transplant. 2002]
Review High intensity regimens with autologous hematopoietic stem cell transplantation as treatment of multiple myeloma.
Awedan AA. Ann Transplant. 2002; 7(2):38-43.
Review Chemotherapy for resistant and relapsing multiple myeloma. [Eur J Haematol Suppl. 1989]
Review Chemotherapy for resistant and relapsing multiple myeloma.
Alexanian R, Barlogie B, Ventura G. Eur J Haematol Suppl. 1989; 51:140-4.

See reviews... See all...

Cited by 3 PubMed Central articles

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. [Haematologica. 2010]
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
Lahuerta JJ, Mateos MV, Martínez-López J, Grande C, de la Rubia J, Rosiñol L, Sureda A, García-Laraña J, Díaz-Mediavilla J, Hernández-García MT, et al. Haematologica. 2010 Nov; 95(11):1913-20. Epub 2010 Jul 27.
Review The Arkansas approach to therapy of patients with multiple myeloma. [Best Pract Res Clin Haematol. ...]
Review The Arkansas approach to therapy of patients with multiple myeloma.
Barlogie B, Anaissie E, van Rhee F, Pineda-Roman M, Zangari M, Shaughnessy J, Epstein J, Crowley J. Best Pract Res Clin Haematol. 2007 Dec; 20(4):761-81.
VAD chemotherapy as remission induction for multiple myeloma. [Br J Cancer. 1995]
VAD chemotherapy as remission induction for multiple myeloma.
Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, Fitzsimmons L, Ryder D. Br J Cancer. 1995 Feb; 71(2):326-30.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell suppo...
High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.
Bone Marrow Transplant. 1990 Apr ;5(4):265-8.

PubMed
Involvement of reactive oxygen species in TGF-beta1-induced tropoelastin express...
Involvement of reactive oxygen species in TGF-beta1-induced tropoelastin expression by human dermal fibroblasts.
Photochem Photobiol. 2009 Nov-Dec ;85(6):1425-33.

PubMed
Possible involvement of GABAergic mechanism in protective effect of melatonin ag...
Possible involvement of GABAergic mechanism in protective effect of melatonin against sleep deprivation-induced behaviour modification and oxidative damage in mice.
Fundam Clin Pharmacol. 2009 Aug ;23(4):439-48.

PubMed
Current status of malaria chemotherapy and the role of pharmacology in antimalar...
Current status of malaria chemotherapy and the role of pharmacology in antimalarial drug research and development.
Fundam Clin Pharmacol. 2009 Aug ;23(4):387-409.

PubMed
Microbial diversity along a transect of agronomic zones.
Microbial diversity along a transect of agronomic zones.
FEMS Microbiol Ecol. 2002 Mar 1 ;39(3):183-91.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support for refractory multiple myeloma.

Source

Abstract

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Other Literature Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information